Synthetic ion-exchange resins were first made available to industry in 1935 and have since been extensively adapted to . . . From the Cardio-Renal Laboratory, Second (Cornell) Medical Division, ...

New findings have important implications in the new era where delaying dialysis initiation is a priority goal by means of continued conservative management of hyperkalemia, according to investigators.

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients with hyperkalemia were prescribed renin-angiotensin-aldosterone system inhibitors for HF.

Please provide your email address to receive an email when new articles are posted on . In this video, David E. Lanfear, MD, advanced HF specialist and program director of the Advanced Heart Failure ...

WASHINGTON, DC—The oral potassium-binding agent patiromer (Veltassa; Vifor Pharma) may help keep hyperkalemia under control in heart failure with reduced ejection fraction (HFrEF) patients taking ...

QRS interval widening appears to be highly specific for the diagnosis of hyperkalemia in patients with end-stage kidney disease. ECG changes, in general, have poor sensitivities for hyperkalemia in ...

The American Society of Nephrology (ASN) today released its latest Kidney Health Guidance (KHG) addressing how potassium and phosphorus additives impact health risks (hyperkalemia and CKD-mineral and ...

Special Late-Breaking Clinical Science Abstract: Effects of Anti-Inflammatory Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis Receive the the latest news, research, and ...